AstraZeneca PLC (AZN)
| Market Cap | 211.12B |
| Revenue (ttm) | 51.21B |
| Net Income (ttm) | 6.50B |
| Shares Out | 1.55B |
| EPS (ttm) | 4.15 |
| PE Ratio | 32.51 |
| Forward PE | 15.08 |
| Dividend | $1.48 (2.19%) |
| Ex-Dividend Date | Aug 9, 2024 |
| Volume | 5,085,816 |
| Open | 67.74 |
| Previous Close | 66.60 |
| Day's Range | 67.59 - 68.38 |
| 52-Week Range | 60.47 - 87.68 |
| Beta | 0.18 |
| Analysts | Buy |
| Price Target | 88.80 (+30.67%) |
| Earnings Date | Feb 6, 2025 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $88.8, which is an increase of 30.67% from the latest price.
News
5 Ideal Buys From 14 'Safer' January Dividends On Bloomberg 2025 Watch List Of 50
Bloomberg Intelligence analysts identified 50 watchable firms for 2025, focusing on catalysts like new leadership, asset sales, acquisitions, and new products. 14 of 35 dividend-paying companies meet ...
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients
On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc's AZN Datroway (datopotamab deruxtecan or Dato-DXd) for adult patients with unresectable or metastatic hormone receptor ...
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against AstraZeneca PLC
LOS ANGELES, CA / ACCESS Newswire / January 21, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZe...
AstraZeneca (AZN) Reels from China Investigation and Investor Suit – Hagens Berman
SAN FRANCISCO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a s...
AstraZeneca PLC Is Being Sued For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 20, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZe...
AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector
My thesis initiates coverage of big pharma stock AstraZeneca, with an initial buy rating, agreeing with today's bullish consensus. Positive upside is driven by the diverse portfolio of solutions to me...
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer.
US FDA approves AstraZeneca's drug for breast cancer
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Friday.
AstraZeneca overhauls management of its China division, FT reports
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general manager, the Financial Times reported on Friday, citing two people with direct kn...
CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previous...
AstraZeneca PLC Is Being Sued For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / January 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZe...
AstraZeneca (AZN) Reels from China Investigation and Investor Suit–Hagens Berman
SAN FRANCISCO, Jan. 15, 2025 (GLOBE NEWSWIRE) -- AstraZeneca (NASDAQ: AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a s...
AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights – AZN
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN).
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZenecaTo Contact Him Directly To Discuss Their Options If you...
Josh Brown's 'best stocks in the market'
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's 'Halftime Report' to update his 'best stocks in the market' list.
Trade Tracker: Jim Lebenthal buys Astrazeneca
Jim Lebenthal, chief equity strategist at Cerity Partners, joins CNBC's 'Halftime Report' to explain why he's buying the drugmaker.
AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses. February 21, 2025 Deadline to file Lead Plaintiff Motion
Investors can contact the law firm at no cost to learn more about recovering their losses
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted and granted Priority Review in the US fo...
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acce...
AstraZeneca (AZN) Reels from China Investigation and Investor Suit - Hagens Berman
AZN Investors with Losses Encouraged to Contact the Firm SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2025 / AstraZeneca (NASDAQ:AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price t...
BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma
LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® respo...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AstraZeneca
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In AstraZeneca To Contact Him Directly To Discuss Their Options NEW Y...
AstraZeneca (AZN) Reels from China Investigation and Investor Suit– Hagens Berman
SAN FRANCISCO, CA / ACCESSWIRE / January 7, 2025 / AstraZeneca (NASDAQ:AZN), the Anglo-Swedish pharmaceutical giant, has seen its stock price tumble 15 percent over the past six months, buffeted by a ...
Deadline Approaching: AstraZeneca PLC (AZN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming February 21, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who...